Swaroop Vitta, MD
Gastroenterology · Birmingham, ALNPI 1942650023
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Sanofi at 57.6% of the total. 2025 is the largest year on record at $10,492, more than ten times the $191 reported in 2019. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $45.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- Johnson & Johnson$1K
- AbbVie$839
- Medtronic$647
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$457
- Bristol Myers Squibb$342
- plus $3K from 28 others
What the payments were for
- Consulting fees$7,20048%
- Travel & lodging$8446%
- Food & beverage$6,78745%
- Education$2922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 22 | $8,717 |
| Johnson & Johnson | 67 | $1,333 |
| AbbVie | 49 | $839 |
| Medtronic | 11 | $647 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $457 |
| Bristol Myers Squibb | 20 | $342 |
| Pfizer | 19 | $288 |
| QOL Medical, LLC | 12 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $263 |
| Ardelyx, Inc. | 13 | $249 |
| Lilly USA, LLC | 12 | $215 |
| E.r. Squibb & Sons, L.L.C. | 2 | $184 |
| Aimmune Therapeutics, Inc. | 10 | $165 |
| Celltrion USA Inc. | 7 | $136 |
| Endogastric Solutions, Inc | 1 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $122 |
| Cook Medical LLC | 2 | $109 |
| Regeneron Healthcare Solutions, Inc. | 5 | $104 |
| Gilead | 5 | $87 |
| Intercept Pharmaceuticals, Inc. | 5 | $81 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Madrigal Pharmaceuticals | 2 | $41 |
| Merck | 2 | $41 |
| Novo Nordisk | 2 | $35 |
| Bayer | 2 | $31 |
| AstraZeneca | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Evoke Pharma, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $22 |
| Enterra Medical, Inc. | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Merit Medical Systems Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,124 in reported general payments places this provider in the 90th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $203,839 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $59,204 |
| LinzessLinaclotide | 71 | $50,375 |
| XifaxanRifaximin | 19 | $49,220 |
| ZenpepLipase/Protease/Amylase | 20 | $42,290 |
| TrulancePlecanatide | 18 | $12,646 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 85 | $11,503 |
| Budesonide DrBudesonide | 32 | $8,267 |
| Mesalamine | 15 | $6,883 |
| Sucralfate | 74 | $6,759 |
| Balsalazide Disodium | 21 | $4,013 |
| Mesalamine ErMesalamine | 12 | $3,613 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 22 | $3,551 |
| Esomeprazole Magnesium | 35 | $2,880 |
| Colestipol Hcl | 25 | $2,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $457 | $73,368122 claims |
| AbbVieLinzess | $839 | $50,37571 claims |
| Aimmune Therapeutics, Inc.Zenpep | $165 | $42,29020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Birmingham
- Robert ShafferBirmingham$1M
- Mukul MehraBirmingham$193K
- Meagan GrayBirmingham$113K
- David SteeleBirmingham$47K
- Kirk RussBirmingham$38K
- Kenneth SigmanBirmingham$34K
- Shajan PeterBirmingham$31K
- Ali AhmedBirmingham$27K
- Rajat ParikhBirmingham$14K
- James CallawayBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.